BBIO - BridgeBio Pharma to acquire remaining 36.3% shares in Eidos Therapeutics

BridgeBio Pharma (BBIO) and Eidos Therapeutics (EIDX) have entered into an agreement under which BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing ~36.3% of outstanding shares.Eidos stockholders will have the right to receive, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share up to an aggregate maximum of $175M of cash.BridgeBio will be able to invest in novel formulations and studies of acoramidis to maximize its long-term potential benefit to ATTR patients, as well as developing its commercial infrastructure. Eidos completed screening in September for its Phase 3 ATTRibute-CM clinical trial of acoramidis in patients with ATTR cardiomyopathy. The study is expected to enroll more than 600 subjects with either wild-type or variant TTR across more than 80 sites in 18 countries.Topline results from Part A are expected in late 2021 or early 2022

For further details see:

BridgeBio Pharma to acquire remaining 36.3% shares in Eidos Therapeutics